Enterococcal endocarditis: Can we win the war?

Jose M. Munita, Cesar A. Arias, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Treatment of enterococcal infections has long been recognized as an important clinical challenge, particularly in the setting of infective endocarditis (IE). Furthermore, the increase prevalence of isolates exhibiting multidrug resistance (MDR) to traditional anti-enterococcal antibiotics such as ampicillin, vancomycin and aminoglycosides (high-level resistance) poses immense therapeutic dilemmas in hospitals around the world. Unlike IE caused by most isolates of Enterococcus faecalis, which still retain susceptibility to ampicillin and vancomycin, the emergence and dissemination of a hospitalassociated genetic clade of multidrug resistant Enterococcus faecium, markedly limits the therapeutic options. The best treatment of IE MDR enterococcal endocarditis is unknown and the paucity of antibiotics with bactericidal activity against these organisms is a cause of serious concern. Although it appears that we are winning the war against E. faecalis, the battle rages on against isolates of multidrug-resistant E. faecium.

Original languageEnglish (US)
Pages (from-to)339-349
Number of pages11
JournalCurrent Infectious Disease Reports
Issue number4
StatePublished - Aug 2012


  • Enterococcus
  • Infective endocarditis
  • Multi-drug resistant enterococci
  • Therapy
  • Vancomycin resistance

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Enterococcal endocarditis: Can we win the war?'. Together they form a unique fingerprint.

Cite this